Classical pediatric Hodgkin lymphoma in very young patients: the Italian experience

Piero Farruggia1, Giuseppe Puccio2, Francesco Locatelli3

  • 1a Pediatric Hematology and Oncology Unit Oncology Department , A.R.N.A.S. Ospedali Civico Di Cristina e Benfratelli , Palermo , Italy.

Leukemia & Lymphoma
|October 11, 2018
PubMed

Insights

Younger children with classic Hodgkin lymphoma (cHL) have better outcomes. An age cutoff of 7 years identified low-risk pediatric patients, though age wasn't an independent factor.

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Cancer Research

Background:

  • Younger patients with Hodgkin lymphoma (HL) often exhibit more favorable outcomes.
  • Identifying specific age-related risk factors is crucial for optimizing pediatric cancer treatment.

Purpose of the Study:

  • To determine an optimal age cutoff for identifying low-risk pediatric patients with classic Hodgkin lymphoma (cHL).
  • To characterize the natural history of classic Hodgkin lymphoma in very young patients.

Main Methods:

  • Retrospective analysis of 135 very young patients diagnosed with classic Hodgkin lymphoma.
  • Statistical evaluation to identify the best age cutoff for risk stratification.
  • Comparison of event-free survival (EFS) and progression-free survival (PFS) between age groups.

Main Results:

  • An age cutoff of 7 years was identified as optimal for distinguishing risk groups.
  • Significantly better EFS (p=.0451) and PFS (p=.00921) were observed in patients younger than 7 years.
  • Ten-year overall survival (OS) rates were 97.0% for younger patients versus 92.5% for older patients (p=.0448).

Conclusions:

  • While younger patients with cHL show better outcomes, age is not an independent prognostic factor.
  • The improved prognosis in younger children appears linked to more favorable initial disease characteristics.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
262
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
304
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
226
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
296
Classical Conditioning01:18

Classical Conditioning

Associative learning, a core principle in behavioral psychology, involves forming connections between events and facilitating learned responses. This concept is vividly illustrated by classical conditioning, a process extensively studied by the Russian physiologist Ivan Pavlov. Pavlov's pioneering research on dogs' digestive systems led to the discovery that behaviors can be learned through association, laying the groundwork for classical conditioning.
Ivan Pavlov observed that dogs...
2.2K
Principles of Classical Conditioning01:23

Principles of Classical Conditioning

Classical conditioning, as described by Ivan Pavlov, is a foundational concept in associative learning, where a neutral stimulus becomes capable of eliciting a conditioned response through association with an unconditioned stimulus. The process of acquisition, where this learning occurs, and the subsequent phenomena of contiguity, contingency, generalization, discrimination, extinction, and spontaneous recovery are crucial for a comprehensive understanding of classical conditioning.
During the...
1.9K